Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in vitro studies-Reference-Cited by-同舟云学术

Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in vitro studies

Published:2022-08 Issue: Volume:45 Page:100459
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Makino Chie,Watanabe Akiko^ORCID,Kato Manabu,Shiozawa Hideyuki,Takakusa Hideo,Nakai Daisuke,Honda Tomoyo,Watanabe Nobuaki^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference28 articles.

1. Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study;Inagaki;BMJ Open Diabetes Res Care,2017

2. Safety and pharmacokinetics of DS-8500a, a novel GPR119 agonist, after multiple oral doses in healthy Japanese males;Kato;Clin Drug Invest,2018

3. DS-8500a, an orally available G protein-coupled receptor 119 agonist, upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats;Matsumoto;J Pharmacol Exp Therapeut,2018

4. In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions;Makino;Xenobiotica,2019

5. Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560;Bateman;J Mass Spectrom,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans;Pharmacology Research & Perspectives;2024-09-10

2. Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [ ¹⁴ C]aficamten following single oral dose administration to rats;Xenobiotica;2024-08-07

3. Recommendations on the Use of Multiple Labels in Human Mass Balance Studies;Drug Metabolism and Disposition;2024-01-12